Search for Genetic Modifiers of PSC: Time to Increase the Number of Needles in the Haystack
Journal Title: Annals of Hepatology - Year 2017, Vol 16, Issue 6
Abstract
Primary sclerosing cholangitis (PSC) belongs to the most obscure liver diseases. Patients with progressive PSC require liver transplantation as only therapeutic option. Previously several HLA- and non-HLA-associated PSC risk variants have been discovered, however their involvement in the development of PSC seems to be minor in comparison to environmental determinants. Lately, variant rs853974 at the RSPO3 gene locus has been shown to modulate the course of PSC. Here we briefly discuss the phenotypes related to this polymorphism and propose alternative directions of research that might help to identify new genetic modifiers of PSC progression.
Authors and Affiliations
Marcin Krawczyk, Frank Lammert
Keywords
Related Articles
- EP ID EP227993
- DOI 10.5604/01.3001.0010.5271
- Views 112
- Downloads 0
NASH: A glance at the landscape of pharmacological treatment
The role of nonalcoholic fatty liver disease, namely nonalcoholic steatohepatitis (NASH), as risk factor for liver- and non-liver-related morbidity and mortality has been extensively reported. In addition to lifestyle c...
SALLuting a new biomarker in hepatocellular carcinoma
Treatment of polycystic liver disease: a hypothesis, patient characteristics, short and long-term results
Background. Non-total liver resecting invasive treatment of polycystic liver disease has different recurrence rates. The aim of this study is to illustrate why the recurrence rates are different. We established a hypothe...
Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging
Background. Staging systems have considerable impact on hepatocellular carcinoma (HCC) treatment approaches and outcomes. There is an unmet need to improve their stratification ability. We have evaluated four commonly us...
Hepatic Hydrothorax
Hepatic hydrothorax (HH) is a pleural effusion that develops in a patient with cirrhosis and portal hypertension in the absence of cardiopulmonary disease. Although the development of HH remains incompletely understood,...